(Q40844552)

24 September 2017

title

Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). (English)

1 reference

24 September 2017

1 reference

1

1 reference

24 September 2017

4

1 reference

24 September 2017

6

1 reference

24 September 2017

Sacchi A

2

1 reference

24 September 2017

Borgna L

series ordinal

3

1 reference

24 September 2017

Gasparri A

series ordinal

5

1 reference

24 September 2017

publication date

1 November 2000

1 reference

24 September 2017

1 reference

24 September 2017

volume

18

1 reference

24 September 2017

issue

11

1 reference

24 September 2017

page(s)

1185-1190

1 reference

An endotoxin-induced serum factor that causes necrosis of tumors

24 September 2017

cites work

1 reference

7 January 2021

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma

1 reference

7 January 2021

Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial

1 reference

7 January 2021

Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study

1 reference

7 January 2021

Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver

1 reference

7 January 2021

Tumour necrosis factor: strategies for improving the therapeutic index

1 reference

7 January 2021

Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas

1 reference

7 January 2021

Modulation of endothelial cell hemostatic properties by tumor necrosis factor

1 reference

7 January 2021

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

1 reference

7 January 2021

Alpha v integrins as receptors for tumor targeting by circulating ligands.

1 reference

7 January 2021

Tumor targeting with a selective gelatinase inhibitor

1 reference

7 January 2021

A mouse aminopeptidase N is a marker for antigen-presenting cells and appears to be co-expressed with major histocompatibility complex class II molecules

1 reference

7 January 2021

Aminopeptidases: structure and function

1 reference

7 January 2021

Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities

1 reference

7 January 2021

In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion

1 reference

7 January 2021

Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion

1 reference

7 January 2021

Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience

1 reference

7 January 2021

Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism

1 reference

7 January 2021

Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor

1 reference

7 January 2021

Tumor Necrosis Factor (TNF) α quantification by ELISA and bioassay: effects of TNFα-soluble TNF receptor (p55) complex dissociation during assay incubations

1 reference

7 January 2021

Chromogranin A fragments modulate cell adhesion. Identification and characterization of a pro-adhesive domain

1 reference

7 January 2021

Identifiers

DOI

10.1038/81183

1 reference

Dimensions Publication ID

24 September 2017

1004929050

0 references

1 reference